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Abstract
Background: The Hospital Acquired Condition Strategy (HACS) denies payment for venous thromboembolism (VTE) after
total knee arthroplasty (TKA). The intention is to reduce complications and associated costs, while improving the quality of
care by mandating VTE prophylaxis. We applied a system dynamics model to estimate the impact of HACS on VTE rates, and
potential unintended consequences such as increased rates of bleeding and infection and decreased access for patients
who might benefit from TKA.
Methods and Findings: The system dynamics model uses a series of patient stocks including the number needing TKA,
deemed ineligible, receiving TKA, and harmed due to surgical complication. The flow of patients between stocks is
determined by a series of causal elements such as rates of exclusion, surgery and complications. The number of patients
harmed due to VTE, bleeding or exclusion were modeled by year by comparing patient stocks that results in scenarios with
and without HACS. The percentage of TKA patients experiencing VTE decreased approximately 3-fold with HACS. This
decrease in VTE was offset by an increased rate of bleeding and infection. Moreover, results from the model suggest HACS
could exclude 1.5% or half a million patients who might benefit from knee replacement through 2020.
Conclusion: System dynamics modeling indicates HACS will have the intended consequence of reducing VTE rates.
However, an unintended consequence of the policy might be increased potential harm resulting from over administration
of prophylaxis, as well as exclusion of a large population of patients who might benefit from TKA.
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Introduction
Recent public debate on health care reform has renewed focus
on patient safety and cost containment [1]. A value-based health
care strategy strives to ‘bend the healthcare cost curve’ by
publically reporting rates of post-operative complications and
adherence to quality of care and patient safety measures [2].
Value-based systems assume institutions will minimize complica-
tion rates thereby costs will be reduced while improving the quality
of care. Value-based mandates, however, may have unintended
consequences on overall complications, unanticipated costs, or
reduced access for individuals who may benefit from a treatment.
As a part of the Deficit Reduction Act of 2005, the Secretary of
Health and Human Services (USA) identified high cost and high
volume procedures where preventable hospital acquired condi-
tions were reimbursed at higher rates [3]. For example, total knee
arthroplasty (TKA) patients who develop venous thromboembo-
lism (VTE), a term used to collectively describe deep vein
thrombosis (DVT) and pulmonary embolism (PE), accrue higher
costs than those who do not experience this condition. Evidence-
based guidelines suggest administering prophylaxis medications
(anti-clotting blood thinners) reduces VTE rates [4,5,6]. To
encourage adherence to these guidelines, beginning on October 1,
2008, the ‘‘hospital acquired condition’’ strategy (HACS) no
longer reimburses inpatient costs after a newly diagnosed VTE if
recommended prophylaxis was not administered prior to TKA
procedures [7].
Every year in the U.S., over 185,000 VTE cases are diagnosed
in patients aged 45 years or older [8]. More than 35% occur after
surgical events [9], frequently leading to long-term disability or
death [10,11]. Certain clinical conditions, such as malignant
neoplasm, trauma, congestive heart failure, obesity, multiparity,
advancing age and hypercoagulability increase VTE risk
[12,13,14]. Despite evidence suggesting its efficacy to reduce
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recommended VTE prophylaxis [15,16]. Patients receiving TKA
have increased risk of VTE, and recommended prophylaxis
reduces this risk [17]. Therefore, a policy that encourages anti-
thrombotic prophylaxis seems reasonable.
System Dynamics [18] has been used to model the consequenc-
es of national smoking cessation initiatives [19], smallpox
vaccination [20], and prevention vs. management of chronic
disease, [21]. Changes in health care policy can affect access,
reimbursement and clinical outcomes. Complex interrelationships
have multiple clinical ramifications on patients, payors, providers,
and hospital administrators. System Dynamics uses stock and flow
diagrams, feedback loops and various ‘what if scenarios’ to portray
the casual relationships among these elements and predict long
term implications of these complex interactions [22]. For example,
improving adherence to prophylaxis guidelines may decrease VTE
rates, but this may also increase the rates of bleeding which in turn
may increase infection rates. Mandating VTE prophylaxis may
reduce access to TKA for patients who have increased risk of
bleeding.
This study applies system dynamics to estimate the impact of
HACS on rates of VTE and other surgical complications (such as
bleeding and infection). We hypothesize that the increased rates of
VTE prophylaxis will actually increase rates of bleeding and
infection [23]. Additionally, patient subgroups who might benefit
from a knee replacement but have increased risk of bleeding will
accumulate.
Methods
Modeling Context
The Hospital Acquired Condition Strategy (HACS) enacted by
federal legislation applied to Medicare reimbursement for VTE
[7]. The majority of patients eligible for Medicare are older than
age 65, and VTE risk varies considerably by age [24], so patients
younger than age 65 were excluded when developing parameters
for the model. Typical Medicare reimbursement to hospitals is
$10,000, $13,000 for patients with a major comorbidity or those
who experience a complication [25]. The rationale for imple-
menting the HACS were the low rates of guideline-recommended
proplylaxis [26]. Some argue is neither preventable nor accurately
measurable [27]. Nearly half of patients with a DVT detectable by
ultrasound do not experience clinical symptoms [28]. Patients with
DVT risk factors will more likely receive prophylaxis and can be
excluded from HACS policy by indicating ‘‘presence on admission
can not be determined’’ [29]. On the other hand, clinicians may
be hesitant to administer DVT prophylaxis to patients with
increased risk of bleeding so these patients might be affected by the
policy change.
Literature Review
Citations from the Federal Register ‘‘hospital acquired condi-
tion’’ policy [7] and the Surgeon General’s Call to Action to
prevent DVT and PE [30] were used to define an initial set of risk
factors and rates of DVT, PE, and bleeding in various populations
as well as potential risk factors. Additional studies were identified
through PubMed database by taking the intersection of each risk
factor and the terms venous thrombosis, DVT, PE, or DVT
prophylaxis.
Expert Interview
Certain model inputs such as willingness to treat patients with
increased risk of DVT or bleeding, rates of surgical site infection in
patients with excessive bleeding, and those harmed by DVT and
bleeding were not clearly described in the literature. Three
arthroplasty surgeons at the University of California, San
Francisco (UCSF) were queried to obtain a range for these values
through mutual agreement. (Refer Information S1 -Questions
asked to expert panel) All three surgeons are board certified knee
specialists performing a large volume of total knee replacement
procedures in a University hospital setting.
Model Parameters
The parameters included in the model are either stocks,
represented as boxes in Figure 1 or causal elements represented
at the ends of arrows. Stocks, accumulate over time with the
quantity regulated by influx and efflux rates. For example, the
stock of patients who can benefit with TKA increase as the
number of patients with osteoarthritis in the overall population
increases. Meanwhile, patients deemed ineligible and those who
receive TKA decrease this stock. The causal elements affect results
derived from the model but do not accumulate over time. An
example of a causal element is the percentage of patients receiving
TKA or fraction of patients with postoperative bleeding who later
developed a surgical site infection.
Model Relationships
The movement of patients through the system is regulated by
the relationships between the stocks and causal elements. A flow is
represented by a thick, double-lined arrow emerging out of or
entering into a stock. Causal links illustrating the effect of the
causal variables are represented by thin arrows. Blue arrows
represent causal effects that may increase or decrease flows, red
and green arrows indicate the impact of HACS.
Policy Intervention
We compare two simulation scenarios, with and without HACS.
The HACS scenario represents the potential result of withholding
reimbursement for hospital care associated with the treatment of
VTE when VTE prophylaxis is not administered prior to TKA.
VTE rates are those indicated when Enoxaparin, the prophylaxis
recommened by both the American College of Chest Physicians
(ACCP) [5] and the American Academy of Orthopaedic Surgeons
(AAOS) [6], is or is not administered. We assume VTE rates
reported in clinical trials would be achieved with increased
adherence to VTE prophylaxis guidelines.
Dynamics Hypothesis
The ideal scenario as envisioned by those who implemented
HACS policy is a hypothesis that rates of VTE will decrease over
time, while rates of surgical complications and disparity remain
stable.
The Systems Dynamics Model
Vensim software was used to design and simulate the System
Dynamics model [18]. The first parameter illustrated in Figure 1 is
the stock representing the prevalence (9.7 million) of patients over
age 65 suffering with symptomatic knee osteoarthritis (OA) [24].
As the model cycles from 2008 through 2020, the number of
patients in this stock is dependent on birth and death rates. The
number of patients requiring TKA are those with OA who do not
respond to non-operative therapy. These patients could either
undergo TKA or be excluded, depending on eligibility require-
ments. The stock entitled ‘‘Patients with Knee OA requiring TKA
who will NOT be operated’’ represents patients with clinical
conditions (such as malignant neoplasm, morbid obesity, immobile
standing position, hypercoagulable state, etc) who are not eligible
System Dynamics for Total Knee Arthroplasty
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e30578for TKA. Patients undergoing TKA could have an uneventful
course, a VTE, or a bleeding complication. Patients who
experience excess bleeding may develop a surgical site infection
resulting from hematoma, evacuation or prolonged wound
drainage [31,32]. Of those experiencing VTE, a fraction will die
due to fatal PE, some have to undergo at least 6 months of oral
anticoagulation, and those who will not be diagnosed with VTE
may experience chronic venous insufficiency requiring long term
mechanical compression therapy. We modeled four complication
scenarios (bleeding, infection, diagnosed and undiagnosed VTE),
with fractions of harmed patients.
The model examined hypothetical simulations over a period of
12 years from 2008 continued through 2020. The stocks examined
were the number of patients experiencing VTE, bleeding,
infection, or were deemed ineligible for surgery individually, as
well as the cumulative number of harmed patients per year. Inputs
for the model are indicated in Table 1. The parameters assume a
1.5% decrease (from 14.4–12.9%) in TKA eligibility among
patients with OA with HACS. Higher rates of bleeding (9.6% vs.
1.4%) and lower rates of VTE (2 vs. 5%) due to increased
administrating VTE prophylaxis with HACS. We also speculate
that a fraction of VTE diagnoses (25 vs. 15%) will be missed
because of a disincentive with HACS to identify the condition, and
that 10% of patients with a missed diagnosis will be harmed. The
range of values for each parameter that were modeled in the
sensitivity analyses are also indicated in Table 1.
Results
Model stock outputs indicate HACS results in a 3-fold decrease
in VTE rates (Table 2). However, the fraction of HACS with
bleeding complications associated is 6-fold higher, and 6-fold more
patients are potentially ineligible for TKA per year with HACS in
place.
The cumulative potential harm over time due to VTE, bleeding,
infection and denied access that could be attributed to HACS is
illustrated in Figure 2. The model indicates the fraction harmed
with HACS will be 2.8 times higher in 2011, 3.3 times in 2014, 3.4
times in 2017 and 3.5 times in 2020. The increase in the total
number of adults harmed by the HACS reaches half a million
people by year 2020. Sensitivity analysis indicates this increase
might be as small as 43,000 and as high as 980,000.
The fraction of patients affected by policy stabilizes as the model
reaches equilibrium (Figure 3). HACS increased the percentage of
patients suffering from OA pain who could benefit from, but do
not receive TKA by 1.6% (2.2% with HACS, 0.6% without).
Figure 1. An illustration of the stocks, causal elements, relationships and impact of HACS in the system dynamics model.
doi:10.1371/journal.pone.0030578.g001
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with HACS may be as high as 3.4% and as low as 0.95%, and
0.79–0.36% without.
Discussion
Several interventions [33], including physician alerts [34],
decision support informatics [35], and regular audits [36] are
shown to increase the rates of VTE prophylaxis. Despite these
efforts, only 60% of TKA patients receive enoxaparin as
recommended by ACCP guidelines [16]. The monetary incentive
mandated by HACS, not reimbursing costs resulting from VTE
when VTE prophylaxis was not administered, was effective for
decreasing VTE rates, but our model suggests HACS will result in
an overall 6-fold increase in complication rates. While others have
suggested the possibility of unintended consequences [37], this
study indicates half a million people might be harmed by HACS
by the year 2020. Furthermore, the fraction of Americans who
could benefit, but are denied for TKA is increased 1.6% with
HACS because of their risk of developing a VTE complication
which would place the providers and hospitals at financial risk for
the episode of care.
Mandating VTE prophylaxis increases the risk of prolonged
wound drainage, extended hospital stay, and surgical site infection
[31,32,38]. Surgical site infection measureably reduces health-
related quality of life [39]. We did not attempt to estimate whether
savings to Medicare by refusing to reimburse care for VTE
complications with HACS is offset by the cost of prophylaxis,
extended hospitalization and readmission resulting from bleeding
and infection complications. Other potential model parameters
were not studied as well. The efficacy of recommended
prophylaxis to reduce the risk of death due to a PE when
compared to aspirin in TKA patients remains controversial [6].
Other prophylaxis regimens may result in a different impact of
HACS. Bleeding rates for this study were based on published
clinical experience with low molecular weight heparin.
A policy that penalizes the occurrence of adverse outcomes will
likely decrease access to at-risk patients. The potential for inequity
may be greater than estimated in this model. Kahneman’s
Prospect Theory suggests aversion of loss is psychologically twice
as powerful as the potential for gain [40]. The desire to avoid
HACS consequences could result in overly aggressive VTE
prophylaxis, under reporting of VTE, and exclusion of patients
who could benefit from TKA. Our model estimates the policy will
exclude over 35,000 patients/year. Access to care is driven by
perceptions of both the surgeon and patient. Only a third of
surveyed patients with painful osteoarthritis were willing to
consider TKA as a treatment option [41]. TKA significantly
improves the quality of life of patients with osteoarthritis
[42,43,44]. Typical patients experience a gain of more than one
quality adjusted life year (QALY from 6.8 to 8.0 with TKA) [45].
Elderly patients with comorbidity and those living in poverty
might be comparable to those who are excluded by HACS. These
patients experienced a similar QALY gain, (0.8, 5.8 to 6.6 with
TKA) [45].
Table 1. Model parameters, minimum and maximum range, and reference sources.
Baseline (%)
Sensitivity Analysis
(minimum - maximum
value) Reference
Without HACS With HACS Without HACS With HACS
Eligibility rate 14.4% 12.9% 13.4–15.4% 11.9–13.9% [49,59], Expert panel
Bleeding rate 1.4% 9.6% 0.4–2.4% 7.6–10.6% [60]
VTE rate 5% 2% 3–7% 0.5–4% [21, 61, 62]
VTE diagnosis rate 85% 75% 75–90% 65–85% Expert panel
Infection rate 10% 10% 5–20% 5–20% [32,33,38] Expert panel,
Bleeding harm rate 58% 58% 46–70% 46–70% [62]
VTE harm rate 75% 75% 65–85% 65–85% [63], Expert panel
Missed diagnosis harm
rate
10% 10% 5–20% 5–20% [64], Expert panel
doi:10.1371/journal.pone.0030578.t001
Table 2. Model outputs indicating the number of harmed
patients per year.
Time (Year) 2008 2011 2014 2017 2020
VTE without HACS 19,500 20,560 21,279 21,679 22,040
VTE with HACS 19,500 8,050 7,661 7,770 7,898
Diagnosed VTE without HACS 16,575 17,151 17,913 18,316 18,631
Diagnosed VTE with HACS 16,575 7,428 5,834 5,803 5,892
Missed VTE without HACS 2,925 3,027 3,161 3,232 3,288
Missed VTE with HACS 2,925 2,359 1,939 1,934 1,964
Bleeding patients without
HACS
5,460 5,757 5,958 6,070 6,171
Bleeding patients with HACS 5,460 34,659 36,593 37,288 37,909
Bleeding without infection
without HACS
4,914 5,085 5,311 5,430 5,524
Bleeding without infection
with HACS
4,914 27,238 32,387 33,347 33,931
Infection without HACS 546 565 590 603 614
Infection with HACS 546 3,026 3,602 4,705 3,770
Ineligible patients without
HACS
00000
Ineligible patients with HACS 0 35,751 38,543 39,335 39,993
Total harmed without HACS 0 15,698 17,175 17,689 18,018
Total harmed with HACS 0 51,387 64,038 66,454 67,680
doi:10.1371/journal.pone.0030578.t002
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monetary incentives to improve adherence to recommended care
guidelines. ‘‘Pay for performance’’ (P4P) rewards increased
adherence to quality metrics [46] while ‘‘hospital acquired
condition’’ penalizes undesirable outcomes. The amount of
increased guideline adherence varies across studies [47,48,49],
Figure 2. The fraction of patients harmed by HACS over time including sensitivity analysis adjustments.
doi:10.1371/journal.pone.0030578.g002
Figure 3. The fraction % of patients with osteoarthritis who might benefit from, but not receive TKA.
doi:10.1371/journal.pone.0030578.g003
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racial disparity [46,49]. Underserved patients may experience
significant out-of-pocket costs so they may delay seeking of care,
both for the OA leading to TKA, but also for post-surgical
monitoring of emerging complications. An alternative to the
current approaches for rewarding guideline-based care might be to
reward those who provide high quality and equitable access to
underserved patients [48,53].
Although our study quantifies the relative impact of intended
and unintended consequences of the HACS policy, the model has
some limitations. First, model inputs were based on assumptions
drawn from publications. In cases where the data could not be
directly extracted from the literature and only approximations
were available, expert opinions from three surgeons in an
academic healthcare setting were obtained. Surgeons in other
settings may have opinions that differ, resulting in a greater or
lesser likelihood to treat patients with risk factors. However, the
dynamic nature of the model allows changing model parameters
whenever desired. Second, the relationship between age and
complication rates, or the effectiveness of VTE prophylaxis by risk
profile is not well documented in the literature. Consequences of
aggressive prophylaxis and the tendency to deny surgery to
subgroups of underserved patients were disregarded and would
need special attention. Third, we did not stratify complications by
severity. So potentially lethal and less harmful complications were
included in the same stock.
Our objective was to provide a range of potential outcomes
resulting from the Hospital Acquired Condition Strategy. A logical
extension could determine how HACS differently impacts various
at-risk populations. While it seems logical to propose process
variables such as VTE prophylaxis administration for measuring
quality of care, it is also clear that VTE is a problematic outcome
because it can occur even with proper prophylaxis [54,55,56,57].
Enforcing policies to prevent VTE can decrease access to care and
pose a theoretical risk of increasing overall complication rates.
Supporting Information
Information S1 Questions asked to expert panel.
(DOC)
Acknowledgments
Team ‘‘Research on Research’’ for 1. templates for writing introduction
and discussion sections of the manuscript [58] and 2. templates for
literature review [59].
Author Contributions
Conceived and designed the experiments: RP MW GZ JS BY ST MM TV.
Performed the experiments: RP MW GZ JS BY ST TV. Analyzed the
data: RP MW GZ JS. Wrote the paper: RP MW GZ JS BY ST MM TV.
References
1. Kohn LT, Corrigan J, Donaldson MS (2000) To err is human : building a safer
health system. Washington, D.C.: National Academy Press. xxi: 287.
2. Porter ME, Teisberg EO (2006) Redefining Health Care: Creating Value-Based
Competition on Results: Harvard Business Press %@ 1591397782 %7 1.
3. (2010) Hospital-Acquired Conditions (Present on Admission Indicator). Centers
for Medicare & Medicaid Services.
4. Kakkar AK, Cohen AT, Tapson VF, Bergmann J-F, Goldhaber SZ, et al. (2010)
Venous thromboembolism risk and prophylaxis in the acute care hospital setting
(ENDORSE survey): findings in surgical patients. Annals of Surgery 251: 330–
338 %U http://www.ncbi.nlm.nih.gov/pubmed/20054273.
5. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, et al. (2008)
Prevention of Venous Thromboembolism*. Chest 133: 381S–453S %U http://
chestjournal.chestpubs.org/content/133/386_suppl/381S.abstract.
6. Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, et al. (2009)
Prevention of symptomatic pulmonary embolism in patients undergoing total
hip or knee arthroplasty. The Journal of the American Academy of Orthopaedic
Surgeons 17: 183–196 %U http://www.ncbi.nlm.nih.gov/pubmed/19264711.
7. (2008) Medicare program: changes to the hospital inpatient prospective payment
systems and fiscal year 2009 rates; payments for graduate medical education in
certain emergency situations; changes to disclosure of physician ownership in
hospitals and physician self-referral rules; updates to the long-term care
prospective payment system; updates to certain IPPS-excluded hospitals; and
collection of information regarding financial relationships between hospitals.
Final rules. : Fed Regist 73(161).
8. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, et al. (2004)
Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal
investigation of thromboembolism etiology. The American Journal of Medicine
117: 19–25 %U http://www.ncbi.nlm.nih.gov/pubmed/15210384.
9. Goldhaber SZ, Tapson VF (2004) A prospective registry of 5,451 patients with
ultrasound-confirmed deep vein thrombosis. The American Journal of
Cardiology 93: 259–262 %U http://www.ncbi.nlm.nih.gov/pubmed/
14715365.
10. Heit JA (2006) The epidemiology of venous thromboembolism in the
community: implications for prevention and management. Journal of Throm-
bosis and Thrombolysis 21: 23–29 %U http://www.ncbi.nlm.nih.gov/pubmed/
16475038.
11. Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P (2007)
Venous thromboembolism and subsequent hospitalisation due to acute arterial
cardiovascular events: a 20-year cohort study. Lancet 370: 1773–1779 %U
http://www.ncbi.nlm.nih.gov/pubmed/18037081.
12. White RH, Gettner S, Newman JM, Trauner KB, Romano PS (2002) Predictors
of rehospitalization for symptomatic venous thromboembolism after total hip
arthroplasty. The New England Journal of Medicine 343: 1758–1764 %U
http://www.ncbi.nlm.nih.gov/pubmed/11114314.
13. Heit JA, O’Fallon WM, Petterson TM, Lohse CM, Silverstein MD, et al. (2002)
Relative impact of risk factors for deep vein thrombosis and pulmonary
embolism: a population-based study. Archives of Internal Medicine 162: 1245–
1248 %U http://www.ncbi.nlm.nih.gov/pubmed/12038942.
14. Rogers SO, Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, et al. (2007)
Multivariable predictors of postoperative venous thromboembolic events after
general and vascular surgery: results from the patient safety in surgery study.
Journal of the American College of Surgeons 204: 1211–1221 %U http://www.
ncbi.nlm.nih.gov/pubmed/17544079.
15. Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, et al. (2007) Multicenter
evaluation of the use of venous thromboembolism prophylaxis in acutely ill
medical patients in Canada. Thrombosis Research 119: 145–155 %U http://
www.ncbi.nlm.nih.gov/pubmed/16516275.
16. Cohen AT, Tapson VF, Bergmann J-F, Goldhaber SZ, Kakkar AK, et al. (2008)
Venous thromboembolism risk and prophylaxis in the acute hospital care setting
(ENDORSE study): a multinational cross-sectional study. Lancet 371: 387–394
%U http://www.ncbi.nlm.nih.gov/pubmed/18242412.
17. Turpie AGG, Lassen MR, Davidson BL, Bauer KA, Gent M, et al. (2009)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee
arthroplasty (RECORD4): a randomised trial. Lancet 373: 1673–1680 %U
http://www.ncbi.nlm.nih.gov/pubmed/19411100.
18. Sterman J, Sterman JD (2000) Business Dynamics: Systems Thinking and
Modeling for a Complex World with CD-ROM: McGraw-Hill/Irwin %@
007238915X.
19. Abrams DB, Graham AL, Levy DT, Mabry PL, Orleans CT (2010) Boosting
population quits through evidence-based cessation treatment and policy.
American Journal of Preventive Medicine 38: S351–363%U http://www.ncbi.
nlm.nih.gov/pubmed/20176308.
20. Bozzette SA, Boer R, Bhatnagar V, Brower JL, Keeler EB, et al. (2003) A model
for a smallpox-vaccination policy. The New England Journal of Medicine 348:
416–425 %U http://www.ncbi.nlm.nih.gov/pubmed/12496353.
21. Homer JB, Hirsch GB (2006) System dynamics modeling for public health:
background and opportunities. Am J Public Health 96: 452–458.
22. Sterman JD (2006) Learning from evidence in a complex world. Am J Public
Health 96: 505–514.
23. Streiff MB, Haut ER (2009) The CMS ruling on venous thromboembolism after
totalknee or hip arthroplasty:weighing risksand benefits.JAMA 301:1063–1065.
24. Jordan JM, Helmick CG, Renner JB, Luta G, Dragomir AD, et al. (2007)
Prevalence of knee symptoms and radiographic and symptomatic knee
osteoarthritis in African Americans and Caucasians: the Johnston County
Osteoarthritis Project. The Journal of Rheumatology 34: 172–180 %U http://
www.ncbi.nlm.nih.gov/pubmed/17216685.
25. Wachter RM, Foster NE, Dudley RA (2008) Medicare’s decision to withhold
payment for hospital errors: the devil is in the det. Joint Commission Journal on
Quality and Patient Safety/Joint Commission Resources 34: 116–123 %U
http://www.ncbi.nlm.nih.gov/pubmed/18351196.
26. Nutescu EA, Shorr AF, Farrelly E, Horblyuk R, Happe LE, et al. (2008) Burden
of deep vein thrombosis in the outpatient setting following major orthopedic
System Dynamics for Total Knee Arthroplasty
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e30578surgery. The Annals of Pharmacotherapy 42: 1216–1221 %U http://www.ncbi.
nlm.nih.gov/pubmed/18611992.
27. Pronovost PJ, Goeschel CA, Wachter RM (2008) The wisdom and justice of not
paying for ‘‘preventable complications’’. JAMA: The Journal of the American
Medical Association 299: 2197–2199 %U http://www.ncbi.nlm.nih.gov/
pubmed/18477787.
28. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, et al.
(1991) A population-based perspective of the hospital incidence and case-fatality
rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT
Study. Archives of Internal Medicine 151: 933–938 %U http://www.ncbi.nlm.
nih.gov/pubmed/2025141.
29. Prandoni P (2005) Acquired risk factors for venous thromboembolism in medical
patients. Hematology/the Education Program of the American Society of
Hematology American Society of Hematology Education Program: 458–461
%U http://www.ncbi.nlm.nih.gov/pubmed/16304420.
30. (2008) The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis
and Pulmonary Embolism. In: Services UDoHaH, ed. Washington DC.
31. Patel VP, Walsh M, Sehgal B, Preston C, DeWal H, et al. (2007) Factors
associated with prolonged wound drainage after primary total hip and knee
arthroplasty. The Journal of Bone and Joint Surgery American Volume 89: 33–
38 %U http://www.ncbi.nlm.nih.gov/pubmed/17200307.
32. Galat DD, McGovern SC, Hanssen AD, Larson DR, Harrington JR, et al.
(2008) Early return to surgery for evacuation of a postoperative hematoma after
primary total knee arthroplasty. The Journal of Bone and Joint Surgery
American Volume 90: 2331–2336 %U http://www.ncbi.nlm.nih.gov/pubmed/
18978401.
33. Tooher R, Middleton P, Pham C, Fitridge R, Rowe S, et al. (2005) A systematic
review of strategies to improve prophylaxis for venous thromboembolism in
hospitals. Annals of Surgery 241: 397–415 %U http://www.ncbi.nlm.nih.gov/
pubmed/15729062.
34. Piazza G, Rosenbaum EJ, Pendergast W, Jacobson JO, Pendleton RC, et al.
(2009) Physician alerts to prevent symptomatic venous thromboembolism in
hospitalized patients. Circulation 119: 2196–2201 %U http://www.ncbi.nlm.
nih.gov/pubmed/19364975.
35. Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E (2000) A clinical
decision support system for prevention of venous thromboembolism: effect on
physician behavior. JAMA: The Journal of the American Medical Association
283: 2816–2821 %U http://www.ncbi.nlm.nih.gov/pubmed/10838650.
36. Byrne GJ, McCarthy MJ, Silverman SH (1996) Improving uptake of prophylaxis
for venous thromboembolism in general surgical patients using prospective
audit. BMJ (Clinical Research Ed) 313: 917 %U http://www.ncbi.nlm.nih.gov/
pubmed/8876095.
37. Streiff MB, Haut ER (2009) The CMS ruling on venous thromboembolism after
total knee or hip arthroplasty: weighing risks and benefits. JAMA: The Journal of
the American Medical Association 301: 1063–1065 %U http://www.ncbi.nlm.
nih.gov/pubmed/19278950.
38. Saleh K, Olson M, Resig S, Bershadsky B, Kuskowski M, et al. (2002) Predictors
of wound infection in hip and knee joint replacement: results from a 20 year
surveillance program. Journal of Orthopaedic Research: Official Publication of
the Orthopaedic Research Society 20: 506–515 %U http://www.ncbi.nlm.nih.
gov/pubmed/12038624.
39. Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ (2002)
The impact of surgical-site infections following orthopedic surgery at a
community hospital and a university hospital: adverse quality of life, excess
length of stay, and extra cost. Infection Control and Hospital Epidemiology: The
Official Journal of the Society of Hospital Epidemiologists of America 23: 183–
189 %U http://www.ncbi.nlm.nih.gov/pubmed/12002232.
40. Kahneman D, Tversky A (1979) Prospect Theory: An Analysis of Decision
under Risk. Econometrica 47: 263–291 %U http://www.jstor.org/stable/
1914185.
41. Hawker GA, Wright JG, Badley EM, Coyte PC (2004) Perceptions of, and
willingness to consider, total joint arthroplasty in a population-based cohort of
individuals with disabling hip and knee arthritis. Arthritis and Rheumatism 51:
635–641 %U http://www.ncbi.nlm.nih.gov/pubmed/15334438.
42. Norman-Taylor FH, Palmer CR, Villar RN (1996) Quality-of-life improvement
compared after hip and knee replacement. The Journal of Bone and Joint
Surgery British Volume 78: 74–77 %U http://www.ncbi.nlm.nih.gov/pubmed/
8898131.
43. Ra ¨sa ¨nen P, Paavolainen P, Sintonen H, Koivisto A-M, Blom M, et al. (2007)
Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life
years and costs. Acta Orthopaedica 78: 108–115 %U http://www.ncbi.nlm.nih.
gov/pubmed/17453401.
44. Ballal RD, Botteman MF, Foley I, Stephens JM, Wilke CT, et al. (2008)
Economic evaluation of major knee surgery with recombinant activated factor
VII in hemophilia patients with high titer inhibitors and advanced knee
arthropathy: exploratory results via literature-based modeling. Current Medical
Research and Opinion 24: 753–768 %U http://www.ncbi.nlm.nih.gov/
pubmed/18234151.
45. Losina E, Walensky RP, Kessler CL, Emrani PS, Reichmann WM, et al. (2009)
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and
hospital volume. Archives of Internal Medicine 169: 1113–1121; discussion
1121–1122 %U http://www.ncbi.nlm.nih.gov/pubmed/19546411.
46. Rosenthal MB, Dudley RA (2007) Pay-for-performance: will the latest payment
trend improve care? JAMA 297: 740–744.
47. McDonald R, White J, Marmor TR (2009) Paying for performance in primary
medical care: learning about and learning from ‘‘success’’ and ‘‘failure’’ in
England and California. Journal of Health Politics, Policy and Law 34: 747–776
%U http://www.ncbi.nlm.nih.gov/pubmed/19778931.
48. Rosenthal MB, Dudley RA (2007) Pay-for-Performance. JAMA: The Journal of
the American Medical Association 297: 740–744 %U http://jama.ama-assn.
org/content/297/747/740.short.
49. Millett C, Netuveli G, Saxena S, Majeed A (2009) Impact of pay for
performance on ethnic disparities in intermediate outcomes for diabetes: a
longitudinal study. Diabetes Care 32: 404–409.
50. Werner RM, Asch DA, Polsky D (2005) Racial profiling: the unintended
consequences of coronary artery bypass graft report cards. Circulation 111:
1257–1263 %U http://www.ncbi.nlm.nih.gov/pubmed/15769766.
51. Millett C, Gray J, Saxena S, Netuveli G, Khunti K, et al. (2007) Ethnic
disparities in diabetes management and pay-for-performance in the UK: the
Wandsworth Prospective Diabetes Study. PLoS Med 4: e191.
52. Millett C, Gray J, Bottle A, Majeed A (2008) Ethnic disparities in blood pressure
management in patients with hypertension after the introduction of pay for
performance. Ann Fam Med 6: 490–496.
53. Chien AT, Chin MH, Davis AM, Casalino LP (2007) Pay for performance,
public reporting, and racial disparities in health care: how are programs being
designed? Medical Care Research and Review: MCRR 64: 283S–304S %U
http://www.ncbi.nlm.nih.gov/pubmed/17881629.
54. Brown J, Doloresco Iii F, Mylotte JM (2009) ‘‘Never events’’: not every hospital-
acquired infection is preventable. Clinical Infectious Diseases: An Official
Publication of the Infectious Diseases Society of America 49: 743–746 %U
http://www.ncbi.nlm.nih.gov/pubmed/19624274.
55. Kirsch M (2009) Medical quality: never events or never never land? The
American Journal of Gastroenterology 104: 2671–2672 %U http://www.ncbi.
nlm.nih.gov/pubmed/19888233.
56. Duska LR, Garrett L, Henretta M, Ferriss JS, Lee L, et al. (2010) When ‘never-
events’ occur despite adherence to clinical guidelines: the case of venous
thromboembolism in clear cell cancer of the ovary compared with other
epithelial histologic subtypes. Gynecologic Oncology 116: 374–377 %U http://
www.ncbi.nlm.nih.gov/pubmed/19922988.
57. Fry DE, Pine M, Jones BL, Meimban RJ (2010) Patient characteristics and the
occurrence of never events. Archives of Surgery (Chicago, Ill: 1960) 145: 148–
151 %U http://www.ncbi.nlm.nih.gov/pubmed/20157082.
58. Shah J, Shah A, Pietrobon R (2009) Scientific writing of novice researchers:
what difficulties and encouragements do they encounter? Acad Med 84:
511–516.
59. Pietrobon R, Taylor M, Guller U, Higgins LD, Jacobs DO, et al. (2004)
Predicting gender differences as latent variables: summed scores, and individual
item responses: a methods case study. Health Qual Life Outcomes 2: 59.
System Dynamics for Total Knee Arthroplasty
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e30578